In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma

Journal of Nuclear Medicine

Volumn 45, Issue 8, 2004, Pages 1334-1339

  Guo, JianFei ^a   Higashi, Kotaro ^a   Yokota, Hajime ^a   Nagao, Yosinobu ^a   Ueda, Yoshimichi ^a   Kodama, Yuko ^a   Oguchi, Manabu ^a   Taki, Suzuka ^a   Tonami, Hisao ^a   Yamamoto, Itaru ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

18F FDG; Choline; Lactate; Lung adenocarcinoma; Magnetic resonance spectroscopy; Prognosis

Indexed keywords

CHOLINE; FLUORODEOXYGLUCOSE F 18; LACTIC ACID; DIAGNOSTIC AGENT; PROTON; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; LUNG ADENOCARCINOMA; MALE; MUSCLE SPASM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; ADENOCARCINOMA; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; JAPAN; LUNG TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY; RISK ASSESSMENT; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; SURVIVAL;

ADENOCARCINOMA; AGED; CHOLINE; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; JAPAN; LACTIC ACID; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROGNOSIS; PROTONS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS; SURVIVAL ANALYSIS;

EID: 4544318626     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Warburg O. The Metabolism of Tumors. New York, NY: Richard Smith; 1931:129-169.
2. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623-648.
3. 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med. 2003;44:192-197.
4. Franzius C, Bielack S, Flege S, Sciuk J, Jurgens H, Schober O. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med. 2002;43:1012-1017.
5. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837-3844.
6. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000;41:85-92.
7. 18F] FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30:78-84.
8. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39-45.
9. Hicks RJ, Kalff V, MacManus MP, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-1604.
10. Dhital K, Saunders CA, Seed PT, O'Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18:425-428.
11. Lear JL. Glycolysis: link between PET and proton MR spectroscopic studies of the brain. Radiology. 1990;174:328-330.
12. 1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys. 2002;52:1271-1276.
13. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000;60:916-921.
14. Herminghaus S, Pilatus U, Moller-Hartmann W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed. 2002;15:385-392.
15. Girard N, Wang ZJ, Erbetta A, et al. Prognostic value of proton MR spectroscopy of cerebral hemisphere tumors in children. Neuroradiology. 1998;40:121-125.
16. 11C-choline PET. J Nucl Med. 2000;41:1507-1513.
17. Pieterman RM, Que TH, Elsinga PH, et al. Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med. 2002;43:167-172.
18. 18F]fluorodeoxyglucose PET in the evaluation of lung cancer. Nucl Med Commun. 2003;24:359-366.
19. 1H-MRS. J Neurooncol. 2003;62:329-338.
20. 1H-NMR spectroscopy. NMR Biomed. 2002;15:37-44.
21. Higashi K, Matsunari I, Ueda Y, et al. Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med. 2003;17:1-14.
22. Higashi K, Ueda Y, Ayabe K, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun. 2000;21:707-714.
23. Schwickert G, Walenta S, Sundfor K, Rofstad E, Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res. 1995;55:4757-4759.
24. Walenta S, Salameh A, Lyng H, et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol. 1997;150:409-415.
25. Burk D, Woods M, Hunter J. On the significance of glucolysis for cancer growth, with special reference to Morris rat hepatomas. J Natl Cancer Inst. 1967;38:839-863.
26. Terpstra M, High WB, Luo Y, de Graaf RA, Merkle H, Garwood M. Relationships among lactate concentration, blood flow and histopathologic profiles in rat C6 glioma. NMR Biomed. 1996;9:185-194.
27. Ikezaki K, Black KL, Conklin SG, Becker DP. Histochemical evaluation of energy metabolism in rat glioma. Neurol Res. 1992;14:289-293.
28. Waki A, Kato H, Yano R, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol. 1998;25:593-597.
29. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38:1337-1344.
30. 18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778-1785.
31. Tamiya T, Kinoshita K, Ono Y, Matsumoto K, Furuta T, Ohmoto T. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology. 2000;42:333-338.
32. Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg. 1996;84:449-458.